Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIP48 vs Pegasys in Chronic Hepatitis C
NCT01623336Phase 3Unknown
- Sponsor
- Immunobiological Technology Institute
- Start
- Jan 2012
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in hepatitis C (HCV) (2 arms), sponsored by Immunobiological Technology Institute. Primary endpoint: Sustained Virologic Response. Status: unknown.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01623336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01623336.